Aptamer Group Regulatory News (APTA)

8 August 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Investor Technical Webinar

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce that Dr David Bunka, Chief Scientific Officer, will host a webinar to provide an update on the Company's progress within its technical development programmes.

The webinar will be broadcast on Thursday, 14 August 2025, at 6:00 pm (BST) and will offer a detailed review of the latest data and technical developments, building on insights shared through recent regulatory announcements.

The webinar is open to shareholders and other interested parties who can register for the event by using the following link: https://www.turnerpope.com/register/

- Ends -

For further information, please contact: 

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

​Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/